Abstract 1596P
Background
Palliative care has shown a positive economic impact in oncology. However, research on its financial viability in oncology, especially in developing countries, is lacking. This study estimates hospitalization costs for cancer patients in the southeast region of Brazil.
Methods
We used a retrospective analysis of electronic medical records for cancer patients treated at a Cancer Center in the southeast region of Brazil. Inclusion criteria were adult patients with any type of cancer who had died at a hospital setting between January 2022 and March 2023. Patients were divided into two groups: those who received outpatient palliative care (OPCT) and those who did not receive any OPCT. Based on the available clinical outcomes of the sample, data was collected on the hospital admission date, length of stay until death, and the type of accommodation until death [admission at intensive care unit (ICU) versus general ward]. To estimate the costs, we used real-world data from private hospitals in the southeast region, measuring the general amounts spent on daily hospitalization and ICU stays, and their respective lengths of stay, without reference to any specific patient or procedures. We performed univariate comparisons using Linear Regression.
Results
Out of the 72 patients with cancer, 29 were followed by the OPCT team, while 43 were not. The average cost of hospitalization for patients who did not receive the OPCT was found to be R$ 20,000.00 (€ 3,651.00; SD = 9.19) higher than those who received OPCT (p = 0.03). We observed that patients who were admitted to the ICU had hospitalization cost, on average, R$ 17,800.00 (€ 3,249.00; SD = 9.61) more than those who stayed in general ward (p = 0.06).
Conclusions
Our study highlights the economic benefits of providing OPCT in a developing country. Based on this analysis, OPCT can reduce healthcare costs by decreasing the length of hospital stay and preventing unnecessary ICU admissions. Our study suggest that policymakers and healthcare providers should prioritize the provision of OPCT in Brazil, and this type of support should be considered as an essential component of end-of-life care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oncoclinicas.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05